Antibody to aquaporin-4 in the long-term course of neuromyelitis optica

Brain

Volumn 131, Issue 11, 2008, Pages 3072-3080

  Jarius, S ^a,b   Aboul Enein, F ^c   Waters, P ^a   Kuenz, B ^d   Hauser, A ^c   Berger, T ^d   Lang, W ^e   Reindl, M ^d   Vincent, A ^a   Kristoferitsch, W ^c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c DANUBE HOSPITAL   (Austria)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^e KRANKENHAUS DER BARMHERZIGEN BRÜDER   (Austria)

Author keywords

Aquaporin 4 antibody; Devic syndrome; Long term follow up; Longitudinally extensive transverse myelitis; Neuromyelitis optica; NMO IgG

Indexed keywords

AQUAPORIN 4; AUTOANTIBODY; AZATHIOPRINE; CD19 ANTIGEN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; IMMUNOGLOBULIN G; METHYLPREDNISOLONE; MITOXANTRONE; PREDNISOLONE; PROTEIN ANTIBODY; RECOMBINANT PROTEIN; RITUXIMAB;

ADOLESCENT; ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; AUTOIMMUNE DISEASE; CENTRAL NERVOUS SYSTEM; CLINICAL ARTICLE; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FLUORESCENCE; HUMAN; IMMUNOPRECIPITATION; IMMUNOSUPPRESSIVE TREATMENT; MALE; MYELOOPTIC NEUROPATHY; PATHOGENESIS; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; ANTIGENS, CD19; AQUAPORIN 4; AUTOANTIBODIES; AUTOIMMUNE DISEASES; AZATHIOPRINE; BIOLOGICAL MARKERS; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; NEUROMYELITIS OPTICA; RECURRENCE; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 55749088210     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awn240     Document Type: Article

References (18)

1. Cree BA, Lamb S, Morgan K, Chen A, Waubant E, Genain C. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005; 64: 1270-2.
2. de Seze J, Stojkovic T, Ferriby D, Gauvrit JY, Montagne C, Mounier-Vehier F, et al. Devic's neuromyelitis optica: clinical, laboratory, MRI and outcome profile. J Neurol Sci 2002; 197: 57-61.
3. Hinson SR, Pittock SJ, Lucchinetti CF, Roemer SF, Fryer JP, Kryzer TJ, et al. Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology 2007; 69: 2221-31.
4. Jarius S, Franciotta D, Bergamaschi R, Wright H, Littleton E, Palace J, et al. NMO-IgG in the diagnosis of neuromyelitis optica. Neurology 2007; 68: 1076-7.
5. Jarius S, Paul F, Franciotta D, Waters P, Zipp F, Hohlfeld R, et al. Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica. Nat Clin Pract Neurol 2008; 4: 202-14.
6. Kazkaz H, Isenberg D. Anti B cell therapy (rituximab) in the treatment of autoimmune diseases. Curr Opin Pharmacol 2004; 4: 398-402.
7. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005; 202: 473-7.
8. Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004; 364: 2106-12.
9. Levesque MC, St Clair EW. B cell-directed therapies for autoimmune disease and correlates of disease response and relapse. J Allergy Clin Immunol 2008; 121: 13-21; quiz 22-3.
10. Lucchinetti CF, Mandler RN, McGavern D, Bruck W, Gleich G, Ransohoff RM, et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002; 125: 1450-61.
11. Misu T, Fujihara K, Kakita A, Konno H, Nakamura M, Watanabe S, et al. Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain 2007; 130: 1224-34.
12. Paul F, Jarius S, Aktas O, Bluthner M, Bauer O, Appelhans H, et al. Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica. PLoS Med 2007; 4: e133.
13. Roemer SF, Parisi JE, Lennon VA, Benarroch EE, Lassmann H, Bruck W, et al. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 2007; 130: 1194-205.
14. Takahashi T, Fujihara K, Nakashima I, Misu T, Miyazawa I, Nakamura M, et al. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain 2007; 130: 1235-43.
15. Waters P, Jarius S, Littleton E, Leite MI, Jacob S, Gray B, et al. Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis. Arch Neurol 2008; 65: 913-9.
16. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999; 53: 1107-14.
17. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol 2007; 6: 805-15.
18. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006; 66: 1485-9.